Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 927

1.

Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review.

Nagafuji H, Yokoi H, Fujiwara M, Sato D, Saito K.

Medicine (Baltimore). 2018 Jun;97(24):e10932. doi: 10.1097/MD.0000000000010932. Review.

2.

Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

Vanichapol T, Chutipongtanate S, Anurathapan U, Hongeng S.

Biomed Res Int. 2018 Feb 25;2018:1812535. doi: 10.1155/2018/1812535. eCollection 2018. Review.

3.

Adult renal neuroblastoma: A case report and literature review.

Huang MD, Hsu LS, Chuang HC, Lin WY, Lin WH, Yen CW, Chen ML.

Medicine (Baltimore). 2018 Apr;97(14):e0345. doi: 10.1097/MD.0000000000010345. Review.

4.

Clinical Presentation, Evaluation, and Management of Neuroblastoma.

Sharma R, Mer J, Lion A, Vik TA.

Pediatr Rev. 2018 Apr;39(4):194-203. doi: 10.1542/pir.2017-0087. Review. No abstract available.

PMID:
29610427
5.

Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

Swift CC, Eklund MJ, Kraveka JM, Alazraki AL.

Radiographics. 2018 Mar-Apr;38(2):566-580. doi: 10.1148/rg.2018170132. Review.

PMID:
29528815
6.

TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy.

Batzke K, Büchel G, Hansen W, Schramm A.

Int J Mol Sci. 2018 Mar 2;19(3). pii: E718. doi: 10.3390/ijms19030718. Review.

7.

Pediatric Supratentorial Ganglioneuroblastoma: Case Report and Review of Literature.

Mirza FA, Synder B, Smith VD, Vasquez RA.

World Neurosurg. 2018 May;113:261-266. doi: 10.1016/j.wneu.2018.02.115. Epub 2018 Feb 26. Review. Erratum in: World Neurosurg. 2018 Aug 14;:.

PMID:
29496580
8.

Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma.

Bell D.

Head Neck Pathol. 2018 Mar;12(1):22-30. doi: 10.1007/s12105-018-0887-5. Epub 2018 Feb 9. Review.

PMID:
29427030
9.

Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

Aygun N.

Curr Pediatr Rev. 2018;14(2):73-90. doi: 10.2174/1573396314666180129101627. Review.

PMID:
29380702
10.

Neuroblastoma.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M.

Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241. doi: 10.1093/jjco/hyx176. Review.

PMID:
29378002
11.

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.

Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S.

Curr Radiopharm. 2018;11(1):14-21. doi: 10.2174/1874471011666171215093112. Review.

PMID:
29243585
12.

Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations.

Callahan MJ, MacDougall RD, Bixby SD, Voss SD, Robertson RL, Cravero JP.

Pediatr Radiol. 2018 Jan;48(1):21-30. doi: 10.1007/s00247-017-4023-6. Epub 2017 Nov 27. Review. Erratum in: Pediatr Radiol. 2018 Jan 25;:.

PMID:
29181580
13.

Current views of common pediatric cancers - an update.

An Q, Fan CH, Xu SM.

Eur Rev Med Pharmacol Sci. 2017 Oct;21(4 Suppl):20-24. Review.

PMID:
29165770
14.

Tobacco, alcohol and illicit drugs during pregnancy and risk of neuroblastoma: systematic review.

Müller-Schulte E, Kurlemann G, Harder A.

Arch Dis Child Fetal Neonatal Ed. 2018 Sep;103(5):F467-F473. doi: 10.1136/archdischild-2017-313615. Epub 2017 Nov 21. Review.

PMID:
29162685
15.

Cancer and Autoimmunity: Paraneoplastic Neurological Disorders Associated With Neuroblastic Tumors.

Mitchell WG, Blaes F.

Semin Pediatr Neurol. 2017 Aug;24(3):180-188. doi: 10.1016/j.spen.2017.08.011. Epub 2017 Sep 1. Review.

PMID:
29103425
16.

Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

Berger M, VON Schweinitz D.

Anticancer Res. 2017 Nov;37(11):5911-5918. Review.

PMID:
29061769
17.

Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

Xia J, Zhang H, Hu Q, Liu SY, Zhang LQ, Zhang A, Zhang XL, Wang YQ, Liu AG.

J Huazhong Univ Sci Technolog Med Sci. 2017 Oct;37(5):649-660. doi: 10.1007/s11596-017-1785-x. Epub 2017 Oct 20. Review.

PMID:
29058276
18.

MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential.

Galardi A, Colletti M, Businaro P, Quintarelli C, Locatelli F, Di Giannatale A.

Curr Med Chem. 2018 Feb 13;25(5):584-600. doi: 10.2174/0929867324666171003120335. Review.

PMID:
28971761
19.

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

Amoroso L, Haupt R, Garaventa A, Ponzoni M.

Expert Opin Investig Drugs. 2017 Nov;26(11):1281-1293. doi: 10.1080/13543784.2017.1380625. Epub 2017 Sep 26. Review.

PMID:
28906153
20.

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR.

Cancer. 2017 Dec 15;123(24):4914-4923. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. Review.

PMID:
28885700

Supplemental Content

Loading ...
Support Center